3 commercial payer policies list C83.39. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
3 policies from 1 payer
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C83.39 |
|---|---|---|
| Ibritumomab Tiuxetan (Zevalin) | Oct 11, 2023 | Covered |
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) | Feb 20, 2024 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |